Blood cancer (AML leukaemia)
A study of venetoclax treatment in patients with acute myeloid leukemia to see if it helps prevent the disease from coming back after initial therapy
Who can joinChildren and adults
Age15–60 years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial CentreMumbaiDirections ↗
Registry summary (technical)
Centre for Advanced Research on Innovation in Diagnosis, Prognostication, and Monitoring of Acute Myeloid Leukemia: VENCON STUDY: A Phase II-III study of Venetoclax- Based Consolidation in AML Patients in CR After Azacitidine + Venetoclax Induction - VENCON
Sponsor: Tata Memorial Centre
CTRI/2026/03/105926 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 27 Apr 2026 · read by us 5 Nov 2026